Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which cur - Predictive marker - Document - PDFSEARCH.IO

First Page	Meta Content
	Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which cur Add to Reading List Document Date: 2014-11-06 23:49:40 Open Document File Size: 35,44 KB Share Result on Facebook Company Medical Oncology Group of Australia / / Currency USD / / IndustryTerm treatment of HER2 positive early breast cancer / / MedicalCondition II disease / HER2 positive early breast cancer / III disease / HER2 positive metastatic breast cancer / breast cancer / tumour / disease / NEOADJUVANT breast cancer / / Organization Pharmaceutical Benefits Advisory Committee / Medicare / / Position consultant physician / Minister / / Product Herceptin / / Technology hybridization / / SocialTag HER2/neu Biology Breast cancer Pharmaceutical Benefits Scheme Health Cancer treatments Predictive marker Breast cancer chemotherapy Medicine Trastuzumab

Item 6.3 Application 1230: HER2 ISH testing for access to trastuzumab for NEOADJUVANT breast cancer. Decision: MSAC advised the Minister that it supports amending the current item descriptor for MBS item 73332, which curAdd to Reading List